As expected, the ALDH2 polymorphism rs671 influenced the effects of ICI therapy on chest malignancies. ALDH2*2 had a negative effect on short-term prognosis, although it was unlikely to affect long-term prognosis. According to multivariable and stratified analyses, the negative effect was independent of sex, smoking habit, PD-L1 expression rate, and EGFR mutation. Compared with EGFR mutation, which has been shown to be associated with poor prognosis independent of ICI or initial ICI efficacy[30, 34], rs671 may be more strongly associated with initial ICI efficacy. However, ALDH2*2 showed no negative effect on long-term survivors, especially the first treatment line group; thus, we found that ALDH2*2 is not consistently associated with negative effects.
Several findings that support the negative impact of ALDH2*2 on the short-term prognosis of ICI therapy have been reported. Gao et al. (2018) showed that drug-induced T-cell hepatitis is suppressed by exogenous acetaldehyde. Mechanistically, aldehyde suppresses the secretion of cytokines by inhibiting the phosphatidylinositol 3-kinase (PI3K)-Akt pathway in T cells or promotes the secretion of glucocorticoids that suppresses the activation of T cells[12]. This suppression of the PI3K-Akt pathway has also been confirmed in the cardiomyocytes of Aldh2−/− mice, in which endogenous aldehydes accumulate in the absence of exogenous aldehyde[35]. These findings suggest that endogenous aldehyde also suppresses the PI3K-Akt pathway in T cells. The PI3K-Akt pathway is important for T cell differentiation[36] and has been shown to decrease the number of T cells in the thymus gland when activity is impaired[37, 38]. In fact, we found that the number of T cells in the peripheral blood of Aldh2−/− mice and ALDH2*2 carriers is low[25]. On the basis of these findings, we hypothesize that ALDH2*2 negatively affects the initial ICI efficacy via suppression of the PI3K-Akt pathway in T cells due to endogenous aldehyde accumulation.
However, as explained above, endogenous aldehyde can also be advantageous. In the present study, the PFS ratio in the rs671(+) group decreased rapidly but was eventually higher than that of the rs671(−) group (0.21 vs. 0.27). For the first-line group, the PFS ratio after 2 years was 0.37 in the rs671(−) group and 0.40 in the rs671(+) group and was substantially higher compared with that in the other groups (the PFS ratio after 2 years was 0.18–0.23 in the rs671(−) and rs671(+) groups after the second-line treatment). This finding suggests that preventing a decrease in the number of T cells caused by pre-ICI treatment may increase the chances of obtaining a good ICI effect, especially in rs671(+) patients because ALDH2*2 carriers have lower T cell counts[25].
The response rate of patients to ICIs is currently insufficient. For example, only 10%–20% of non-small-cell lung cancer (NSCLC)[39, 40] patients respond to this therapy. Therefore, optimal case selection is important. The effects of ICI are affected by the immunity of the host, the intestinal bacterial environment of the host, and tumor tissue factors[41, 42]. The PD-L1 expression level and EGFR mutation rate, which are tumor tissue factors, are currently used as predictors in clinical settings. In the present study, there was no association between the PFS and PD-L1 ratio. However, EGFR mutation was shown to be a negative predictor for rs671(−), as previously reported. It also has been shown that tissue infiltrating lymphocytes and tumor mutation burden can be predictors of treatment effects, although they have not been applied clinically[42-44]. The most significant limitation of these factors is that highly invasive biopsies are required. Because the microenvironment and gene mutations of tumor cells are known to fluctuate dynamically, collecting tumor tissues immediately before treatment is ideal. However, this may often be difficult due to the condition of patients and the site of lesions. Meanwhile, Hatae et al. (2020) recently showed that blood metabolites reflecting the state of intestinal bacteria and tumor-specific T cell rates are good predictors of ICI effects on NSCLC, although there are still difficulties owing to the number of tested parameters after the start of treatment[45]. Ohue et al. (2019) demonstrated that the effects of ICIs on NSCLC could be predicted by tumor antigens in blood samples collected prior to ICI initiation [HR (95% CI) of PFS in antigen-positive patients is 0.4 (0.2 to 0.9)] [46], and its clinical application is expected. Compared with these predictors, the analysis of ALDH2 polymorphisms has some advantages: non-invasive, inexpensive, 100% determinable, and polymorphisms do not change throughout life.
The limitations of the present study are as follows: 1) The sample size was insufficient to establish prognostic factors specific to rs671(+) patients. 2) Because the present study was limited to Japanese patients with chest malignancies who were mostly men, it cannot be generalized to other types of cancers and populations. 3) Because several time-dependent covariates can affect the outcome, such as adverse reactions and types and doses of second and subsequent ICIs, controlling covariates is insufficient for long-term observation. 4) The biological mechanism is not well supported.